Augmedix, a US-based developer of automation healthcare technology, has raised $19m in its series B round that includes investments from a consortium including McKesson Ventures, the eponymous pharmaceutical firm’s corporate venturing unit.
The other investors included Redmile Group, DCM Ventures and Wanxiang Healthcare Investments.
Tom Rodgers, senior vice president and managing director at McKesson Ventures, said: “Augmedix is uniquely positioned to leverage trained medical documentation experts, increasingly enabled by artificial intelligence, to deliver a consumer-grade experience for the clinician that results in more accurate and timely documentation in the most cost-effective manner possible.”
In December 2016, Augmedix added $23m to its coffers thanks to investors including McKesson Ventures, OrbiMed, Redmile Group, Emergence Capital and DCM Ventures.
Founded in 2012, Augmedix has now raised about $80m. Healthcare systems Sutter Health, Dignity Health, Catholic Health Initiatives, TriHealth and an undisclosed fifth peer previously supplied fund to a $17m funding round in April 2016 led by Redmile with support from Emergence and DCM.
Emergence and DCM also invested $7m in a seed round before returning for a $16m series A round in January 2015.
Fifteen national health systems, including Sutter Health, CommonSpirit Health, and US Oncology, representing more than 10% of clinicians in the US, have partnered with Augmedix.
